Key points from article :
London-based LabGenius secured $10 million to develop new protein-based drugs using their AI-powered robotic platform called EVA.
EVA combines machine learning, automation, and synthetic biology to design, conduct, and learn from experiments, potentially discovering novel therapeutics that were previously difficult to identify.
Led by CEO Dr. James Field, the company plans to partner with pharmaceutical companies to bring these drug candidates to market, initially focusing on inflammatory bowel disease.
With this funding, LabGenius will expand their team, enhance their platform, and begin developing their own drug candidates, with a goal of creating new antibody fragments for treating conditions that current antibodies cannot address.
